Keytruda is not only Merck & Co.’s leading product, but also the best-selling drug worldwide, generating over*** billion U.S. dollars in revenue in 2025. The cancer drug with the generic name pembrolizumab increased its revenues in comparison to the previous year.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Merck & Co., & U.S. Securities and Exchange Commission. (February 24, 2026). Revenue of Keytruda from 2014 to 2025 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 27, 2026, from /statistics/1269401/revenues-of-keytruda/
Merck & Co., und U.S. Securities and Exchange Commission. "Revenue of Keytruda from 2014 to 2025 (in million U.S. dollars)." Chart. February 24, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 27, 2026. /statistics/1269401/revenues-of-keytruda/
Merck & Co., U.S. Securities and Exchange Commission. (2026). Revenue of Keytruda from 2014 to 2025 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 27, 2026. /statistics/1269401/revenues-of-keytruda/
Merck & Co., and U.S. Securities and Exchange Commission. "Revenue of Keytruda from 2014 to 2025 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 Feb 2026, /statistics/1269401/revenues-of-keytruda/
Merck & Co. & U.S. Securities and Exchange Commission, Revenue of Keytruda from 2014 to 2025 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1269401/revenues-of-keytruda/ (last visited July 27, 2026)
Revenue of Keytruda from 2014 to 2025 (in million U.S. dollars) [Graph], Merck & Co., & U.S. Securities and Exchange Commission, February 24, 2026. [Online]. Available: /statistics/1269401/revenues-of-keytruda/
